Patents by Inventor Barney S. Graham

Barney S. Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11338033
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: May 24, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey C. Boyington, Barney S. Graham, John R. Mascola, Hadi M. Yassine, Kizzmekia S. Corbett, Syed M. Moin, Lingshu Wang, Masaru Kanekiyo
  • Publication number: 20220072120
    Abstract: Nanoparticles and vaccines containing these nano particles that elicit an immune response against hemagglutinin (HA) proteins from a broad range of influenza viruses are provided. The nanoparticles are made from self-assembling proteins, at least one of which is joined to an immunogenic portion of an influenza HA protein. This immunogenic portion is displayed on the nanoparticle surface, making the nanoparticles useful for vaccinating subjects against influenza virus.
    Type: Application
    Filed: February 7, 2020
    Publication date: March 10, 2022
    Inventors: Masaru Kanekiyo, Barney S. Graham, Seyhan Boyoglu-Barnum, Rebecca A. Gillespie, Neil P. King, Daniel Ellis, Jing Yang Wang, George Ueda, Jorge Fallas
  • Publication number: 20220054419
    Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Barney S. Graham, Masaru Kanekiyo, Hadi M. Yassine
  • Publication number: 20220031834
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Application
    Filed: October 18, 2021
    Publication date: February 3, 2022
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: John R. MASCOLA, Jeffrey C. BOYINGTON, Hadi M. YASSINE, Peter D. KWONG, Barney S. GRAHAM, Masaru KANEKIYO
  • Publication number: 20220002351
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 6, 2022
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Patent number: 11191727
    Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: December 7, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney S. Graham, Masaru Kanekiyo, Hadi M. Yassine
  • Patent number: 11147867
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: October 19, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
  • Patent number: 11130785
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 28, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Patent number: 10898566
    Abstract: The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 26, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney S. Graham, Theodore C. Pierson, Kimberly A. Dowd, John R. Mascola, Wing-pui Kong, Sung-youl Ko, Eun Sung Yang, Wei Shi, Lingshu Wang, Christina R. Demaso, Rebecca S. Pelc, Adrian Creanga, Julie Ledgerwood, Leda R. Castilho
  • Publication number: 20190374633
    Abstract: The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.
    Type: Application
    Filed: July 28, 2017
    Publication date: December 12, 2019
    Inventors: Barney S. GRAHAM, Theodore C. PIERSON, Kimberly A. DOWD, John R. MASCOLA, Wing-pui KONG, Sung-youl KO, Eun Sung YANG, Wei SHI, Lingshu WANG, Christina R. DEMASO, Rebecca S. PELC, Adrian CREANGA, Julie LEDGERWOOD, Leda R. CASTILHO
  • Publication number: 20190345205
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.
    Type: Application
    Filed: November 15, 2017
    Publication date: November 14, 2019
    Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The United States of America, as Represented by the Department of Health and Human Services
    Inventors: Kimberly DOWD, Barney S. GRAHAM, Sung-Youl KO, Wing-Pui KONG, John MASCOLA, Theodore PIERSON, Mayuri SHARMA, Dong Yu
  • Publication number: 20190314490
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: John R. MASCOLA, Jeffrey C. BOYINGTON, Hadi M. YASSINE, Peter D. KWONG, Barney S. GRAHAM, Masaru KANEKIYO
  • Patent number: 10363301
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: July 30, 2019
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
  • Publication number: 20190192651
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Inventors: Jeffrey C. BOYINGTON, Barney S. GRAHAM, John R. MASCOLA, Hadi M. YASSINE, Kizzmekia S. CORBETT, Syed M. MOIN, Lingshu WANG, Masaru KANEKIYO
  • Publication number: 20190117760
    Abstract: The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection.
    Type: Application
    Filed: November 2, 2018
    Publication date: April 25, 2019
    Inventors: Barney S. Graham, Christopher B. Buck, Jeffrey N. Roberts, Teresa R. Johnson, John Nicewonger, Rhonda Kines, John T. Schiller
  • Publication number: 20180319846
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 8, 2018
    Applicant: The United States of America,as represented by the Secretary,Department of Helath and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Patent number: 10017543
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 10, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Publication number: 20180021258
    Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.
    Type: Application
    Filed: December 31, 2015
    Publication date: January 25, 2018
    Inventors: Barney S. GRAHAM, Masaru KANEKIYO, Hadi M. YASSINE
  • Patent number: 9856313
    Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 2, 2018
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia
  • Publication number: 20170202946
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Application
    Filed: May 27, 2015
    Publication date: July 20, 2017
    Inventors: John R. MASCOLA, Jeffrey C. BOYINGTON, Hadi M. YASSINE, Peter D. KWONG, Barney S. GRAHAM, Masaru KANEKIYO